Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Medicine
Published in: Clinical and Experimental Medicine 1/2024

Open Access 01-12-2024 | Celiac Disease | Review

Metabolomics and lipidomics signature in celiac disease: a narrative review

Authors: Mohammad Rostami-Nejad, Nastaran Asri, Sajjad Bakhtiari, Ensieh Khalkhal, Sepehr Maleki, Mostafa Rezaei-Tavirani, Somayeh Jahani-Sherafat, Kamran Rostami

Published in: Clinical and Experimental Medicine | Issue 1/2024

Login to get access

Abstract

Celiac disease (CD) is a chronic immune-mediated inflammatory disease of the small intestine caused by aberrant immune responses to consumed gluten proteins. CD is diagnosed by a combination of the patients reported symptoms, serologic and endoscopic biopsy evaluation of the small intestine; and adherence to a strict gluten-free diet (GFD) is considered the only available therapeutic approach for this disorder. Novel approaches need to be considered for finding new biomarkers to help this disorder diagnosis and finding a new alternative therapeutic method for this group of patients. Metabolomics and lipidomics are powerful tools to provide highly accurate and sensitive biomarkers. Previous studies indicated a metabolic fingerprint for CD deriving from alterations in gut microflora or intestinal permeability, malabsorption, and energy metabolism. Moreover, since CD is characterized by increased intestinal permeability and due to the importance of membrane lipid components in controlling barrier integrity, conducting lipidomics studies in this disorder is of great importance. In the current study, we tried to provide a critical overview of metabolomic and lipidomic changes in CD.
Literature
1.
2.
Taraghikhah N, Ashtari S, Asri N, et al. An updated overview of spectrum of gluten-related disorders: clinical and diagnostic aspects. BMC Gastroenterol. 2020;20:258.PubMedPubMedCentralCrossRef
3.
Calabrò A, Gralka E, Luchinat C, Saccenti E, Tenori L. A metabolomic perspective on coeliac disease. Autoimmune Dis. 2014;2014: 756138.PubMedPubMedCentral
4.
5.
Pepe A, Mandato C, Di Leo T, Boccia G, Lucaroni G, Franci G, et al. Celiac disease on the bed-side: embedding case finding and screening in hospitalized children. Nutrients. 2023;15(23).
6.
Lionetti E, Pjetraj D, Gatti S, Catassi G, Bellantoni A, Boffardi M, et al. Prevalence and detection rate of celiac disease in Italy: results of a SIGENP multicenter screening in school-age children. Dig Liver Dis. 2023;55(5):608–13.PubMedCrossRef
7.
Sciurti M, Fornaroli F, Gaiani F, et al. Genetic susceptibilty and celiac disease: what role do HLA haplotypes play? Acta Biomed. 2018;89:17–21.PubMed
8.
Mansouri M, Dadfar M, Rostami-Nejad M, Ekhlasi G, Shahbazkhani A, Shahbazkhani B. The frequency of HLA-DQ2/DQ8 haplotypes and celiac disease among the first-degree relatives of patients with celiac disease. Gastroenterol Hepatol Bed Bench. 2021;14:36–43.PubMedPubMedCentral
9.
10.
Martínez-Ojinaga E, Molina M, Polanco I, Urcelay E, Núñez C. HLA-DQ distribution and risk assessment of celiac disease in a Spanish center. Rev Esp Enferm Dig. 2018;110:421–6.PubMedCrossRef
11.
12.
Caputo I, Lepretti M, Martucciello S, Esposito C. Enzymatic strategies to detoxify gluten: implications for celiac disease. Enzyme Res. 2010;2010: 174354.PubMedPubMedCentralCrossRef
13.
Kamboj AK, Oxentenko AS. Clinical and histologic mimickers of celiac disease. Clin Transl Gastroenterol. 2017;8.
14.
Sharma N, Bhatia S, Chunduri V, et al. Pathogenesis of celiac disease and other gluten related disorders in wheat and strategies for mitigating them. Front Nutr 2020;7.
15.
Sollid LM. Coeliac disease: dissecting a complex inflammatory disorder. Nat Rev Immunol. 2002;2(9):647–55.PubMedCrossRef
16.
Rostami-Nejad M, Rostami K, Emami MH, Zali MR, Malekzadeh R. Epidemiology of celiac disease in Iran: a review. Middle East J Dig Dis. 2011;3:5.PubMedPubMedCentral
17.
Rostami-Nejad M, Razzaghi Z, Esmaeili S, Rezaei-Tavirani S, Akbarzadeh Baghban A, Vafaee R. Immunological reactions by T cell and regulation of crucial genes in treated celiac disease patients. Gastroenterol Hepatol Bed Bench. 2020;13:155–60.PubMedPubMedCentral
18.
Ganji A, Moghbeli M. Type 1 diabetes and hyperthyroidism in a family with celiac disease after exposure to gluten: a rare case report. Clin Diabetes Endocrinol. 2018;4:24.PubMedPubMedCentralCrossRef
19.
20.
Vacca M, Porrelli A, Calabrese FM, et al. How metabolomics provides novel insights on celiac disease and gluten-free diet: a narrative review. Front Microbiol. 2022;13: 859467.PubMedPubMedCentralCrossRef
21.
Martín-Masot R, Mota-Martorell N, Jové M, Maldonado J, Pamplona R, Nestares T. Alterations in one-carbon metabolism in celiac disease. Nutrients. 2020;12:3723.PubMedPubMedCentralCrossRef
22.
Claudino WM, Quattrone A, Biganzoli L, Pestrin M, Bertini I, Di Leo A. Metabolomics: available results, current research projects in breast cancer, and future applications. J Clin Oncol. 2007;25:2840–6.PubMedCrossRef
23.
Calabrò A, Gralka E, Luchinat C, Saccenti E, Tenori L. A metabolomic perspective on coeliac disease. Autoimmune Dis. 2014;2014.
24.
Bhawal R, Fu Q, Anderson E, Gibson G, Zhang S. Serum metabolomic and lipidomic profiling reveals novel biomarkers of efficacy for benfotiamine in Alzheimer's disease. Int J Mol Sci 2021;22.
25.
Shahid M, Yeon A, Kim J. Metabolomic and lipidomic approaches to identify biomarkers for bladder cancer and interstitial cystitis (Review). Mol Med Rep. 2020;22:5003–11.PubMedPubMedCentralCrossRef
26.
27.
Clish C. Metabolomics: an emerging but powerful tool for precision medicine. Mol Case Stud. 2015;1: a000588.ADSCrossRef
28.
Daviss B. Growing pains for metabolomics: the newest’omic science is producing results–and more data than researchers know what to do with. Scientist. 2005;19:25–9.
29.
Lempp M, Farke N, Kuntz M, Freibert SA, Lill R, Link H. Systematic identification of metabolites controlling gene expression in E. coli. Nat Commun. 2019;10(1):4463.ADSPubMedPubMedCentralCrossRef
30.
Belhaj MR, Lawler NG, Hoffman NJ. Metabolomics and lipidomics: expanding the molecular landscape of exercise biology. Metabolites. 2021;11.
31.
Aimetti M, Cacciatore S, Graziano A, Tenori L. Metabonomic analysis of saliva reveals generalized chronic periodontitis signature. Metabolomics. 2012;8:465–74.CrossRef
32.
Maher AD, Cloarec O, Patki P, et al. Dynamic biochemical information recovery in spontaneous human seminal fluid reactions via 1H NMR kinetic statistical total correlation spectroscopy. Anal Chem. 2009;81(1):288–95.PubMedCrossRef
33.
34.
Wishart DS. Metabolomics for investigating physiological and pathophysiological processes. Physiol Rev. 2019;99(4):1819–75.PubMedCrossRef
35.
Roberts LD, Souza AL, Gerszten RE, Clish CB. Targeted metabolomics. Curr Protoc Mol Biol. 2012;98:30.2.1-.2.24.
36.
Gowda GAN, Zhang S, Gu H, Asiago V, Shanaiah N, Raftery D. Metabolomics-based methods for early disease diagnostics. Expert Rev Mol Diagn. 2008;8:617–33.PubMedCrossRef
37.
Cox DG, Oh J, Keasling A, Colson KL, Hamann MT. The utility of metabolomics in natural product and biomarker characterization. Biochim Biophys Acta Gen Subj. 2014;1840:3460–74.CrossRef
38.
Bertini I, Calabrò A, De Carli V, et al. The metabonomic signature of celiac disease. J Proteome Res. 2009;8:170–7.PubMedCrossRef
39.
Garreta-Lara E, Gómez-Canela C, Campos B, Barata C, Tauler R, Lacorte S. Combined targeted/untargeted analytical and chemometric approaches in the characterization of Daphnia magna metabolomic changes under bisphenol A exposure. Microchem J. 2021;165: 106150.CrossRef
40.
Zhang X, Zhu X, Wang C, Zhang H, Cai Z. Non-targeted and targeted metabolomics approaches to diagnosing lung cancer and predicting patient prognosis. Oncotarget. 2016;7:63437.PubMedPubMedCentralCrossRef
41.
Roberts LD, Souza AL, Gerszten RE, Clish CB. Targeted metabolomics. Curr Protoc Mol Biol. 2012;98(1):30.2.1-.2.24.
42.
Bernini P, Bertini I, Luchinat C, Tenori L, Tognaccini A. The cardiovascular risk of healthy individuals studied by NMR metabonomics of plasma samples. J Proteome Res. 2011;10:4983–92.PubMedCrossRef
43.
Bartsch T, Alfke K, Wolff S, Rohr A, Jansen O, Deuschl G. Focal MR spectroscopy of hippocampal CA-1 lesions in transient global amnesia. Neurology. 2008;70:1030–5.PubMedCrossRef
44.
Oakman C, Tenori L, Claudino W, et al. Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods. Ann Oncol. 2011;22:1295–301.PubMedCrossRef
45.
Sánchez E, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y. Intestinal Bacteroides species associated with coeliac disease. J Clin Pathol. 2010;63:1105–11.PubMedCrossRef
46.
Fathi F, Ektefa F, Oskouie AA, et al. NMR based metabonomics study on celiac disease in the blood serum. Gastroenterol Hepatol Bed Bench. 2013;6:190.PubMedPubMedCentral
47.
Khalkhal E, Rezaei-Tavirani M, Fathi F, et al. Screening of altered metabolites and metabolic pathways in celiac disease using NMR spectroscopy. Biomed Res Int. 2021;2021.
48.
Yuan C, Graham M, Staley C, Subramanian S. Mucosal microbiota and metabolome along the intestinal tract reveal a location-specific relationship. Msystems. 2020;5:e00055-e120.PubMedPubMedCentralCrossRef
49.
McHardy IH, Goudarzi M, Tong M, et al. Integrative analysis of the microbiome and metabolome of the human intestinal mucosal surface reveals exquisite inter-relationships. Microbiome. 2013;1:17.PubMedPubMedCentralCrossRef
50.
Leonard MM, Kenyon V, Valitutti F, Pennacchio-Harrington R, Piemontese P, Francavilla R, et al. Cohort profile: celiac disease genomic, environmental, microbiome and metabolome study; a prospective longitudinal birth cohort study of children at-risk for celiac disease. PLoS ONE. 2023;18(3): e0282739.PubMedPubMedCentralCrossRef
51.
DaFonte TM, Valitutti F, Kenyon V, Locascio JJ, Montuori M, Francavilla R, et al. Zonulin as a biomarker for the development of celiac disease. Pediatrics. 2023.
52.
Leonard MM, Valitutti F, Karathia H, Pujolassos M, Kenyon V, Fanelli B, et al. Microbiome signatures of progression toward celiac disease onset in at-risk children in a longitudinal prospective cohort study. Proc Natl Acad Sci USA. 2021;118(29).
53.
Koenig JE, Spor A, Scalfone N, et al. Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci. 2011;108:4578–85.ADSPubMedCrossRef
54.
Vacca M, Porrelli A, Calabrese FM, et al. How metabolomics provides novel insights on celiac disease and gluten-free diet: a narrative review. Front Microbiol. 2022;13.
55.
Sanz Y, Palma GD, Laparra M. Unraveling the ties between celiac disease and intestinal microbiota. Int Rev Immunol. 2011;30:207–18.PubMedCrossRef
56.
Sánchez E, Donat E, Ribes-Koninckx C, Fernández-Murga ML, Sanz Y. Duodenal-mucosal bacteria associated with celiac disease in children. Appl Environ Microbiol. 2013;79:5472–9.ADSPubMedPubMedCentralCrossRef
57.
Sanz Y, Sánchez E, Marzotto M, Calabuig M, Torriani S, Dellaglio F. Differences in faecal bacterial communities in coeliac and healthy children as detected by PCR and denaturing gradient gel electrophoresis. FEMS Immunol Med Microbiol. 2007;51:562–8.PubMedCrossRef
58.
Wacklin P, Kaukinen K, Tuovinen E, et al. The duodenal microbiota composition of adult celiac disease patients is associated with the clinical manifestation of the disease. Inflamm Bowel Dis. 2013;19(5):934–41.PubMedCrossRef
59.
Kalliomäki M, Satokari R, Lähteenoja H, et al. Expression of microbiota, Toll-like receptors, and their regulators in the small intestinal mucosa in celiac disease. J Pediatr Gastroenterol Nutr. 2012;54:727–32.PubMedCrossRef
60.
Girbovan A, Sur G, Samasca G, Lupan I. Dysbiosis a risk factor for celiac disease. Med Microbiol Immunol. 2017;206:83–91.PubMedCrossRef
61.
Leonard MM, Karathia H, Pujolassos M, et al. Multi-omics analysis reveals the influence of genetic and environmental risk factors on developing gut microbiota in infants at risk of celiac disease. Microbiome. 2020;8:130.PubMedPubMedCentralCrossRef
62.
Wikoff WR, Anfora AT, Liu J, et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci. 2009;106:3698–703.ADSPubMedPubMedCentralCrossRef
63.
Shi T, Feng Y, Liu W, et al. Characteristics of gut microbiota and fecal metabolomes in patients with celiac disease in Northwest China. Front Microbiol. 2022;13:1020977.PubMedPubMedCentralCrossRef
64.
Girdhar K, Dogru YD, Huang Q, et al. Dynamics of the gut microbiome, IgA response, and plasma metabolome in the development of pediatric celiac disease. Microbiome. 2023;11:9.PubMedPubMedCentralCrossRef
65.
Tjellström B, Stenhammar L, Högberg L, et al. Gut microflora associated characteristics in children with celiac disease. Am J Gastroenterol. 2005;100:2784–8.PubMedCrossRef
66.
Caminero A, Nistal E, Herrán AR, et al. Differences in gluten metabolism among healthy volunteers, coeliac disease patients and first-degree relatives. Br J Nutr. 2015;114:1157–67.PubMedCrossRef
67.
Portincasa P, Bonfrate L, Vacca M, et al. Gut microbiota and short chain fatty acids: implications in glucose homeostasis. Int J Mol Sci. 2022;23.
68.
Di Cagno R, De Angelis M, De Pasquale I, et al. Duodenal and faecal microbiota of celiac children: molecular, phenotype and metabolome characterization. BMC Microbiol. 2011;11:1–21.CrossRef
69.
Khalkhal E, Rezaei-Tavirani M, Fathi F, et al. Screening of altered metabolites and metabolic pathways in celiac disease using NMR spectroscopy. Biomed Res Int. 2021;2021:1798783.PubMedPubMedCentralCrossRef
70.
Farnetti S, Zocco MA, Garcovich M, Gasbarrini A, Capristo E. Functional and metabolic disorders in celiac disease: new implications for nutritional treatment. J Med Food. 2014;17:1159–64.PubMedCrossRef
71.
Abenavoli L, Delibasic M, Peta V, Turkulov V, De Lorenzo A, Medić-Stojanoska M. Nutritional profile of adult patients with celiac disease. Eur Rev Med Pharmacol Sci. 2015;19:4285–92.PubMed
72.
Bernini P, Bertini I, Calabrò A, et al. Are patients with potential celiac disease really potential? The answer of metabonomics. J Proteome Res. 2011;10:714–21.PubMedCrossRef
73.
Di Cagno R, De Angelis M, De Pasquale I, et al. Duodenal and faecal microbiota of celiac children: molecular, phenotype and metabolome characterization. BMC Microbiol. 2011;11:219.PubMedPubMedCentralCrossRef
74.
Kirchberg FF, Werkstetter KJ, Uhl O, et al. Investigating the early metabolic fingerprint of celiac disease—a prospective approach. J Autoimmun. 2016;72:95–101.PubMedCrossRef
75.
Sen P, Carlsson C, Virtanen SM, et al. Persistent alterations in plasma lipid profiles before introduction of gluten in the diet associated with progression to celiac disease. Clin Transl Gastroenterol. 2019;10:1–10.PubMedCrossRef
76.
Di Stefano M, Miceli E, Mengoli C, Corazza GR, Di Sabatino A. The effect of a gluten-free diet on vitamin D metabolism in celiac disease: the state of the art. Metabolites. 2023;13.
77.
Upadhyay D, Singh A, Das P, et al. Abnormalities in metabolic pathways in celiac disease investigated by the metabolic profiling of small intestinal mucosa, blood plasma and urine by NMR spectroscopy. NMR Biomed. 2020;33: e4305.PubMedCrossRef
78.
Bertini I, Calabro A, De Carli V, et al. The metabonomic signature of celiac disease. J Proteome Res. 2009;8:170–7.PubMedCrossRef
79.
Tracey TJ, Kirk SE, Steyn FJ, Ngo ST. The role of lipids in the central nervous system and their pathological implications in amyotrophic lateral sclerosis. Semin Cell Dev Biol. 2021;112:69–81.PubMedCrossRef
80.
Ademowo OS, Dias H, Burton DG, Griffiths HR. Lipid (per) oxidation in mitochondria: an emerging target in the ageing process? Biogerontology. 2017;18:859–79.PubMedPubMedCentralCrossRef
81.
Das UN. “Cell membrane theory of senescence” and the role of bioactive lipids in aging, and aging associated diseases and their therapeutic implications. Biomolecules. 2021;11.
82.
Desai AJ, Miller LJ. Changes in the plasma membrane in metabolic disease: impact of the membrane environment on G protein-coupled receptor structure and function. Br J Pharmacol. 2018;175(21):4009–25.PubMedCrossRef
83.
O’Donnell VB, Ekroos K, Liebisch G, Wakelam M. Lipidomics: current state of the art in a fast moving field. Wiley Interdiscip Rev Syst Biol Med. 2020;12: e1466.PubMedCrossRef
84.
Torres M, Parets S, Fernández-Díaz J, et al. Lipids in pathophysiology and development of the membrane lipid therapy: new bioactive lipids. Membranes (Basel). 2021;11.
85.
Züllig T, Trötzmüller M, Köfeler HC. Lipidomics from sample preparation to data analysis: a primer. Anal Bioanal Chem. 2020;412:2191–209.PubMedCrossRef
86.
Fahy E, Cotter D, Sud M, Subramaniam S. Lipid classification, structures and tools. Biochim Biophys Acta Mol Cell Biol Lipids. 2011;1811:637–47.CrossRef
87.
88.
Lam SM, Tian H, Shui G. Lipidomics, en route to accurate quantitation. Biochim Biophys Acta Mol Cell Biol Lipids. 2017;1862:752–61.PubMedCrossRef
89.
90.
Titz B, Gadaleta RM, Lo Sasso G, et al. Proteomics and lipidomics in inflammatory bowel disease research: from mechanistic insights to biomarker identification. Int J Mol Sci. 2018;19:2775.PubMedPubMedCentralCrossRef
91.
Diab J, Hansen T, Goll R, et al. Lipidomics in ulcerative colitis reveal alteration in mucosal lipid composition associated with the disease state. Inflamm Bowel Dis. 2019;25:1780–7.PubMedCrossRef
92.
93.
Lin P-Y, Stern A, Peng H-H, Chen J-H, Yang H-C. Redox and metabolic regulation of intestinal barrier function and associated disorders. Int J Mol Sci. 2022;23:14463.PubMedPubMedCentralCrossRef
94.
Wit M, Trujillo-Viera J, Strohmeyer A, Klingenspor M, Hankir M, Sumara G. When fat meets the gut—focus on intestinal lipid handling in metabolic health and disease. EMBO Mol Med. 2022;14: e14742.PubMedPubMedCentralCrossRef
95.
Ko C-W, Qu J, Black DD, Tso P. Regulation of intestinal lipid metabolism: current concepts and relevance to disease. Nat Rev Gastroenterol. 2020;17:169–83.CrossRef
96.
Pan X, Hussain MM. Gut triglyceride production. Biochim Biophys Acta. 1821;2012:727–35.
97.
D'Aquila T, Hung Y-H, Carreiro A, Buhman KK. Recent discoveries on absorption of dietary fat: presence, synthesis, and metabolism of cytoplasmic lipid droplets within enterocytes. Biochim Biophys Acta Mol Cell Biol Lipids. 2016;1861(8, Part A):730–47.
98.
Monson EA, Trenerry AM, Laws JL, Mackenzie JM, Helbig KJ. Lipid droplets and lipid mediators in viral infection and immunity. FEMS Microbiol Rev. 2021;45:fuaa066.
99.
Steel DM, Ryd W, Ascher H, Strandvik B. Abnormal fatty acid pattern in intestinal mucosa of children with celiac disease is not reflected in serum phospholipids. J Pediatr Gastroenterol Nutr. 2006;43:318–23.PubMedCrossRef
100.
Bene J, Komlósi K, Gasztonyi B, Juhász M, Tulassay Z, Melegh B. Plasma carnitine ester profile in adult celiac disease patients maintained on long-term gluten free diet. World J Gastroenterol. 2005;11:6671.PubMedPubMedCentralCrossRef
101.
Solakivi T, Kaukinen K, Kunnas T, Lehtimäki T, Mäki M, Nikkari ST. Serum fatty acid profile in celiac disease patients before and after a gluten-free diet. Scand J Gastroenterol. 2009;44:826–30.PubMedCrossRef
102.
Sen P, Carlsson C, Virtanen SM, et al. Persistent alterations in plasma lipid profiles before introduction of gluten in the diet associated with progression to celiac disease. Clin Transl Gastroenterol. 2019;10.
103.
Baldi S, Menicatti M, Nannini G, et al. Free fatty acids signature in human intestinal disorders: significant association between butyric acid and celiac disease. Nutrients. 2021;13.
104.
105.
Kochhar GS, Singh T, Gill A, Kirby DF. Celiac disease: managing a multisystem disorder. Cleve Clin J Med. 2016;83:217–27.PubMedCrossRef
106.
Busby E, Bold J, Fellows L, Rostami K. Mood disorders and gluten: It's not all in your mind! A systematic review with meta-analysis. Nutrients. 2018;10.
107.
van Hees NJ, Giltay EJ, Geleijnse JM, Janssen N, van der Does W. DHA serum levels were significantly higher in celiac disease patients compared to healthy controls and were unrelated to depression. PLoS ONE. 2014;9: e97778.ADSPubMedPubMedCentralCrossRef
108.
Harris RB, Foote JA, Hakim IA, Bronson DL, Alberts DS. Fatty acid composition of red blood cell membranes and risk of squamous cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev. 2005;14:906–12.PubMedCrossRef
109.
Riezzo G, Ferreri C, Orlando A, Martulli M, D’Attoma B, Russo F. Lipidomic analysis of fatty acids in erythrocytes of coeliac patients before and after a gluten-free diet intervention: a comparison with healthy subjects. Br J Nutr. 2014;112:1787–96.PubMedCrossRef
110.
Ginocchio VM, Brunetti-Pierri N. Progress toward improved therapies for inborn errors of metabolism. Hum Mol Genet. 2016;25:R27–35.PubMedCrossRef
111.
Agarwal A, Singh A, Mehtab W, et al. Patients with celiac disease are at high risk of developing metabolic syndrome and fatty liver. Intest Res. 2021;19:106–14.PubMedCrossRef
Metadata
Title
Metabolomics and lipidomics signature in celiac disease: a narrative review
Authors
Mohammad Rostami-Nejad
Nastaran Asri
Sajjad Bakhtiari
Ensieh Khalkhal
Sepehr Maleki
Mostafa Rezaei-Tavirani
Somayeh Jahani-Sherafat
Kamran Rostami
Publication date
01-12-2024
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 1/2024
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-024-01295-2

Other articles of this Issue 1/2024

Clinical and Experimental Medicine 1/2024 Go to the issue

Review

Research progress on the multi-omics and survival status of circulating tumor cells

Research

Sex-specific differences in ICOS+ T helper cell differentiation in systemic lupus erythematosus patients with low disease activity

Research

Assessment of bone turnover markers and DXA parameters to predict bone metastasis progression during zoledronate treatment: a single-center experience

Research

Circulating Bone morphogenetic protein 9 (BMP9) as a new biomarker for noninvasive stratification of nonalcoholic fatty liver disease and metabolic syndrome

Research

Ascites fluid calprotectin level is highly accurate in diagnosing spontaneous bacterial peritonitis: a preliminary proof of concept prospective study

Review

WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits